{"id":60437,"date":"2024-02-28T06:48:51","date_gmt":"2024-02-28T06:48:51","guid":{"rendered":"https:\/\/medsname.com\/rioci-1\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"rioci-1","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/rioci-1\/","title":{"rendered":"Rioci 1"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer — What is Rioci 1?<\/h3>\n

Rioci 1<\/strong> is 1 mg riociguat tablets from a WHO-GMP certified manufacturer — a soluble guanylate cyclase (sGC) stimulator for hipertensiunea arterial\u0103 pulmonar\u0103 (HAP)<\/strong>. HAP este o boal\u0103 specific\u0103, progresiv\u0103 \u0219i rar\u0103 \u2014 nu este aceea\u0219i cu hipertensiunea sistemic\u0103<\/strong>. It raises pressure in the pulmonary arteries, not the systemic arteries, and requires dedicated specialist-directed therapy at an accredited PAH centre. Riociguat was introduced by Bayer in 2013 as Adempas<\/strong> — the first sGC stimulator approved for human use. FDA-approved for two specific forms of pulmonary hypertension: pulmonary arterial hypertension (PAH, WHO Group 1) and chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4) — the only oral drug approved for inoperable CTEPH. directly activates soluble guanylate cyclase (the NO receptor) in pulmonary arterial smooth muscle, raising cGMP and producing pulmonary vasodilation. Unlike PDE5 inhibitors, riociguat stimulates sGC even in the absence of NO, giving activity in NO-deficient vascular beds characteristic of PAH and CTEPH. Dosing: Start 1 mg three times daily (8-hour intervals); titrate every 2 weeks by 0.5 mg increments based on systolic BP (must remain >95 mmHg) and symptoms. Target dose 2.5 mg three times daily. PAH treatment is typically combination therapy initiated and monitored at a specialist centre; this is not a DIY disease.<\/p>\n<\/div>\n

\nCe beneficii ofer\u0103 MedsBase:<\/strong> Produc\u0103tor certificat WHO-GMP \u00b7 Ambalaj discret \u00b7 Livrare la nivel mondial \u00b7 Peste 1.400 de recenzii verificate ale clien\u021bilor<\/a>\n<\/div>\n

\ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n

De ce s\u0103 comanzi de la MedsBase<\/h3>\n

Medicamentele noastre generice sunt procurate de la produc\u0103tori certifica\u021bi WHO-GMP \u0219i expediate la nivel mondial \u00een ambalaje discrete \u0219i simple \u2014 f\u0103r\u0103 denumirea medicamentului pe exteriorul coletului. Pl\u0103\u021bile cu cardul sunt procesate printr-un procesor reglementat (descrierile de pe extrasul de cont includ un procesor de pl\u0103\u021bi cu card reglementat \u2014 niciodat\u0103 \u201cMedsBase\u201d sau numele vreunui medicament). Accept\u0103m \u0219i criptomonede \u0219i transferuri bancare SEPA. Fiecare comand\u0103 este sus\u021binut\u0103 de Politica noastr\u0103 de Asigurare pentru Relivrare.<\/p>\n

What Is Rioci 1?<\/h2>\n

Rioci 1 is 1 mg riociguat tablets from a WHO-GMP certified manufacturer, supplied in 10-180 tablets. Riociguat was introduced by Bayer in 2013 as Adempas<\/strong> — the first sGC stimulator approved for human use. FDA-approved for two specific forms of pulmonary hypertension: pulmonary arterial hypertension (PAH, WHO Group 1) and chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4) — the only oral drug approved for inoperable CTEPH.<\/p>\n

Hipertensiunea arterial\u0103 pulmonar\u0103 (HAP) nu este hipertensiune sistemic\u0103.<\/strong> HAP se refer\u0103 \u00een mod specific la cre\u0219terea presiunii \u00een circula\u021bia arterial\u0103 pulmonar\u0103 (\u226520 mmHg presiune arterial\u0103 pulmonar\u0103 medie cu rezisten\u021b\u0103 vascular\u0103 pulmonar\u0103 \u22652 unit\u0103\u021bi Wood conform ghidurilor ESC\/ERS 2022). Este rar\u0103 (estimat\u0103 la 15-50 la un milion de adul\u021bi), progresiv\u0103 \u0219i, f\u0103r\u0103 tratament, are un prognostic slab (supravie\u021buire istoric\u0103 la 5 ani \u223c30%). Terapia modern\u0103 direc\u021bionat\u0103 c\u0103tre HAP a \u00eembun\u0103t\u0103\u021bit supravie\u021buirea la 5 ani la 60-70% \u00een centrele de specialitate.<\/p>\n

Candidates for Rioci 1 have been diagnosed at a PAH specialist centre via right heart catheterisation, with WHO\/NYHA functional class II-IV symptoms and confirmed PAH (WHO Group 1) or — for riociguat — inoperable or persistent CTEPH (WHO Group 4). This is not a drug for ordinary hypertension or for self-initiated therapy.<\/p>\n

How Riociguat Works<\/h2>\n

Directly activates soluble guanylate cyclase (the NO receptor) in pulmonary arterial smooth muscle, raising cGMP and producing pulmonary vasodilation. Unlike PDE5 inhibitors, riociguat stimulates sGC even in the absence of NO, giving activity in NO-deficient vascular beds characteristic of PAH and CTEPH.<\/p>\n

Dovezi<\/h2>\n

PATENT-1 (2013)<\/strong> — riociguat in 443 PAH patients; 6-minute walk distance improved by 30 m vs placebo, with better WHO functional class and delayed clinical worsening. CHEST-1 (2013)<\/strong> — riociguat in 261 inoperable or persistent CTEPH patients; 6-minute walk improved by 46 m vs placebo.<\/p>\n

Doza \u0219i Monitorizare<\/h2>\n

Doza:<\/strong> Start 1 mg three times daily (8-hour intervals); titrate every 2 weeks by 0.5 mg increments based on systolic BP (must remain >95 mmHg) and symptoms. Target dose 2.5 mg three times daily.<\/p>\n

Monitorizare:<\/strong> la evaluarea ini\u021bial\u0103 \u0219i apoi la fiecare 3-6 luni \u2014 clas\u0103 func\u021bional\u0103 WHO, distan\u021ba parcurs\u0103 \u00een 6 minute, NT-proBNP, ecocardiografie repetat\u0103 \u0219i (la intervale mai mari) cateterism cardiac drept. Toate efectuate printr-un centru specializat \u00een HAP.<\/p>\n

BP monitoring:<\/strong> systolic BP must remain >95 mmHg; uptitration paused or reversed on symptomatic hypotension.<\/p>\n

Efecte Secundare<\/h2>\n